心血管系统疾病仍是维持性血液透析患者最常见的并发症。近年来，有相当比例的透析患者接受了经皮冠状动脉介入治疗。冠状动脉支架植入手术后，越来越多的维持性血液透析患者被诊断冠状动脉支架内再狭窄。本文就该类特殊群体独有的危险因素以及冠状动脉支架内再狭窄的影响因素及治疗策略进行综述。
Cardiovascular disease remains the most common complication in maintenance hemodialysis (MHD) patients. In recent years, a significant proportion of dialysis patients have received percutaneous coronary intervention (PCI). An increasing number of MHD patients are being diagnosed with in-stent restenosis after coronary stent implantation. This article reviews the unique risk factors of this special group and the influencing factors and treatment strategies of coronary in-stent restenosis.
［1］Santopinto JJ, Fox KA, Goldberg RJ, et al. Creatinine clearance and adverse hospital outcomes in patients with acute coronary syndromes: findings from the global registry of acute coronary events (GRACE). Heart. 2003, 89(9): 1003-1008.
［2］Gibson CM, Dumaine RL, Gelfand EV, et al. Association of glomerular filtration rate on presentation with subsequent mortality in non-ST-segment elevation acute coronary syndrome; observations in 13,307 patients in five TIMI trials. Eur Heart J. 2004, 25(22): 1998-2005.
［3］Hoffmann R, Mintz GS, Dussaillant GR, et al. Pat-terns and mechanisms of in-stent restenosis: A serial intravascular ultrasound study[J]. Circulation,1996,94(6):1247-1254.
［4］Ross R. Atherosclerosis-an inflammatory disease [J]. N Engl J Med, 1999, 340(2): 115-126.
［5］LIU J，MA KL，GAO M，et al．Inflammation disrupts the LDL receptor pathway and accelerates the progression of vascular calcification in ESRD patients［J］.PLoS One，2012，7 (10) : e47217.
［6］刘继红，李艳丽，孙敏. 超纯透析对维持性血液透析患者6项生化指标及炎症状态的影响[J].中国实用医刊，2016，43(4):10-11.
［7］王丰平，陈民，宋晓英，等. 不同血液净化方式对维持性血液透析患者微炎症状态、血脂及颈动脉内-中膜厚度的影响[J]. 中国医刊，2022，57(2):167-170.
［8］F Li，J Wang，X Yang，et al. Effect of Dialysis Frequency on Microinflammation in Patients with Maintenance Hemodialysis. West Indian Medical Journal，2021，3(69)，140-143.
［9］于霄霖，杨苏民．阿司匹林抵抗相关影响因素的研究进展［J］．中国医药，2019，14(2) : 301-303．
［10］Polzin A, Dannenberg L, Sisone R, et al. Antiplatelet effects of aspirin in chronic kidney disease patients. [J] Thromb Haemost2016,14(2):375-380.
［11］Small DS，Wrishko RE，Ernest CS 2nd，et al．Prasugrel pharmacokinetics and pharmacodynamics in subjects with moderate renal impairment and end-stage renal disease［J］．J Clin Pharm Ther，2009，34( 5) : 585-594．
［12］Alexopoulos D, Xanthopoulou I, Plakomyti T E, et al. Ticagrelor in clopidogrel- resistant patients undergoing maintenance hemodialysis[J]. American Journal of Kidney Diseases, 2012, 60(2): 332-333.
［13］Kim JS，Woo JS，Kim JB，et al．The pharmacodynamics of low and standard doses of ticagrelor in patients with end stage renal disease on hemodialysis［J］.Int J Cardiol 2017，238: 110-116．
［14］谢娟, 李正胜, 卢晶晶, 等.吲哚布芬预防血液透析患者动静脉内瘘血栓形成[J]. 贵州医科大学学报, 2017,42(05):607-610.
